期刊文献+

羟丙基透明质酸的制备及性质研究 被引量:1

Study on Preparation and Properties of Hydroxypropyl Hyaluronic Acid
原文传递
导出
摘要 羟丙基透明质酸(HHA)是环氧丙烷对透明质酸(HA)的羟基修饰的产物。文章对HHA的制备方法及性质进行了研究,通过比较样品溶液在酶作用下粘度变化情况研究了其抗透明质酸酶降解的特性,并以相近相对分子质量的HA作对照考察了其细胞毒性。结果:建立了碱性条件下的HHA的制备方法,确定了HHA具有明显的抗透明质酸酶降解的特性,与HA相比两者的细胞毒性没有明显区别。 Hydroxypropyl hyaluronic acid( HHA) may be obtained by the modification of hydroxyl group of hyaluronic acid( HA)with epoxy propane. The aim of the paper is to study the preparation method and the property of degradation-resisting by hyaluronidase and the cytotoxicity of HHA. Comparison of the rangeability of the sample solution's viscosity with hyaluronidase the property of degradation-resisting by hyaluronidase was studied. Using HA with similar relative molecular mass as reference substance,the cytotoxicity of HHA was studied. The result indicates that the preparation method of HHA which is under a alkaline condition was established. Compared with HA,HHA has evident property of resistance to degrade by hyaluronidase and there is no obvious difference between them about cytotoxicity. The conclusion is that HHA is a safe biomaterial and has better property of degradation-resisting by hyaluronidase.
出处 《药物生物技术》 CAS 2014年第3期214-217,共4页 Pharmaceutical Biotechnology
关键词 透明质酸 修饰 羟丙基透明质酸 透明质酸酶 抗降解 细胞毒性 Hyaluronic acid,Modification,Hydroxypropyl hyaluronic acid,Hyaluronidase,Degradation-resisting,Cytotoxicity
  • 相关文献

参考文献7

二级参考文献37

共引文献70

同被引文献31

  • 1Haag R, Kratz F. Polymer therapeutics:concepts and applications [ J ]. A ngew Chem Int Ed, 2006,45 ( 8 ) : 1198 - 1215.
  • 2Jatzkewitz H. Peptamin ( glycyl-L-leucyl-mescaline ) bound to blood plasma expander (polyvinylpyrrolidone) as a new depot form of a biologically active primary amine ( mescaline ) [ J ]. Z NatugCorseh, 1955,10 : 27 -31.
  • 3Perez H L, Cardarelli P M, Deshpande S, et al. Antibody-drug conjugates : current status and future directions [ J ]. Drug Discov Today,2014,19(7) :869-881.
  • 4Ringsdorf 14. Structure and properties of pharmacologically active polymers [ J ]. J Polym Sci Polym Syrup, 1975,51 ( 1 ) :135-153.
  • 5Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability andthe EPR effect in macromolecular therapeutics : a review [ J ]. J Control Rel,2000,65( 1 ) :271-284.
  • 6Duncan R. Polymer conjugates as anticancer nanomedicines [ J ]. Nature Reviews Cancer,2006,6(9) :688-701.
  • 7Mehvar R. Recent trends in the use of polysaccharides for improved delivery of therapeutic agents: phannacokinetic and pharmacodynamic perspectives [ J]. Curr Pharm Biotechnol, 2003,4(5 ) :283-302.
  • 8Etrych T, ubr V, Strohahn J, et al. HPMA copolymer-doxorubicin conjugates:The effects of molecular weight and architecture on biodistribution and in vivo activity [ J ]. J Control Rel, 2012,164 (3) :346-354.
  • 9Markovsky E, Baabur-Cohen H, Eldar-Boock A,et al. Administra- tion, distribution, metabolism and elimination of polymer thera- peutics[J]. J Control Rel,2012 ,161 (2) :446-460.
  • 10Vercauteren R, Bruneel D, Schacht E,et al. Effect of the chemical modification of dextran on the degradation by dextranase [J ]. J Bioact Compatible Polym, 1990,5 ( 1 ) :4-15.

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部